Clinical Trial

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-12-05; most recent amendment 2026-06-30.
Status change: Not Yet Recruiting → Recruiting 2025-12-17
Trial Details
NCT Number NCT07290283
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Healthy Participants
Enrollment 176 participants
Start Date 2025-12-10
Primary Completion 2026-10-21 (estimated)
Study Completion 2026-10-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-31